If you have been reading about peptide research and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-08-04. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
=== 1970s === During the 1970s several conductors of symphonic orchestras added their voices to the growing international opposition to war in general and to nuclear weapons in particular by hosting concerts which raised public awareness of the dangers which the Cold War posed to world peace. These "Concerts for Peace" received international acclaim and were held in various venues including the Japanese city of Hiroshima (1973), the National Cathedral in Washington D.C. (1973), the United Nations General Assembly in New York City (1974) and the Salzburg Music Festival (1976) by such leading musicians as Leonard Bernstein and Seiji Ozawa. Convinced that "Hiroshima belongs to the world", Ozawa returned to the site of Japan's national peace memorials in both Hiroshima and Nagasaki on multiple occasions to pay homage to the memory of the innocent victims of all wars (1980-2005). These memorial "Concerts for Peace" were conducted in collaboration with several premier international orchestras including: the San Francisco Symphony (1975), the Boston Symphony Orchestra (1978), the New Japan Philharmonic (1982 & 1995), and the Seiji Ozawa Music Academy Orchestra (2005) in a performance of Gabriel Faure's Requiem with a civic chorus of over four hundred voices.
This scenario usually occurs at very low solidification velocities (< 1 μm s−1) or with extremely fine particles because they can move by Brownian motion away from the front. The resultant structure contains no macroporosity. If one were to increase the solidification speed, the size of the particles or solid loading moderately, the particles begin to interact in a meaningful way with the approaching ice front. The result is typically a lamellar or cellular templated structure whose exact morphology depends on the particular conditions of the system. It is this type of solidification that is targeted for porous materials made by freeze-casting. The third possibility for a freeze-cast structure occurs when particles are given insufficient time to segregate from the suspension, resulting in complete encapsulation of the particles within the ice front. This occurs when the freezing rates are rapid, particle size becomes sufficiently large, or when the solids loading is high enough to hinder particle motion. To ensure templating, the particles must be ejected from the oncoming front. Energetically speaking, this will occur if there is an overall increase in free energy if the particle were to be engulfed (Δσ > 0).
Mizell won his first start of 1953, coming within an out of throwing a complete game on April 22 against Cincinnati in an 8–3 victory. On April 28, he held the Phillies to one run for five innings in a tie, as rain forced the game to be called and it was never resumed. His most notable game of the season came on May 4, when he gave up just two hits in a shutout of the Pirates. Mizell had a 2.83 ERA before the All-Star Break, but he had a 4.14 ERA in the second half of the season. On August 7, he held the New York Giants to one run in a complete game, 2–1 triumph. Exactly one week later, he held Cincinnati to one run over nine innings, but the Cardinals only scored one for him. After throwing a scoreless 10th, Mizell took the loss in the 11th when Roy McMillan had an RBI single against him. His 11 strikeouts in that contest were a season-high, and he also had five games in which he had nine, including each of his last two starts. In 33 starts, he had a 13–11 record. For the second year in a row, he led the NL in strikeouts per 9 innings pitched (6.9), and he finished third in the league with 173 strikeouts this time, behind Roberts's 198 and Carl Erskine's 187. His 3.49 ERA was the ninth-best mark in the league, but his 114 walks trailed only Johnny Lindell's 139 for the league lead.
Sources: en.wikipedia.org
== Treatment == It is important for MADD patients to maintain strength and fitness without exercising or working to exhaustion. Learning this balance may be more difficult than normally, as muscle pain and fatigue may be perceived differently from normal individuals. Symptomatic relief from the effects of MADD may sometimes be achieved by administering ribose orally at a dose of approximately 10 grams per 100 pounds (0.2 g/kg) of body weight per day, and exercise modulation as appropriate. Taken hourly, ribose provides a direct but limited source of energy for the cells. Patients with myoadenylate deaminase deficiency do not retain ribose during heavy exercise, so supplementation may be required to rebuild levels of ATP. Creatine monohydrate could also be helpful for AMPD patients, as it provides an alternative source of energy for anaerobic muscle tissue and was found to be helpful in the treatment of other, unrelated muscular myopathies.
The new 23rd district covers southwestern Texas, including the Big Bend, and stretches eastward through Del Rio and Uvalde to the northern San Antonio suburbs including the west side of Stone Oak, Shavano Park and Camp Bullis with a small finger extending eastward to Lackland AFB in southwest San Antonio, and also westward to the eastern fringes of the El Paso suburbs. The incumbent is Republican Tony Gonzales, who was re-elected with 62.3% of the vote in 2024. Democrats are targeting the majority Hispanic district, which has a one-third White minority, and gave Donald Trump and Ted Cruz 56.8% and 52.9% of the vote, respectively, in 2024. Republican leaders called on Gonzales to end his re-election campaign after he admitted to having a sexual relationship with a former staff member who later died by suicide, following his earlier denial of the allegations. Gonzales ended his campaign on March 5, leading to the cancellation of the runoff and making challenger Brandon Herrera the Republican nominee. Gonzales later resigned on April 13 after he was expected to face an expulsion vote alongside Democratic representative Eric Swalwell, who was accused of sexual assault. Swalwell similarly had announced his resignation on April 13, hours before Gonzales' announcement. Despite multiple other vacancies which occurred around the same time having been filled by August, governor Greg Abbott never called an emergency special election to fill this seat, likely leaving it vacant until January 2027.
Humps which mostly contain fat can shrink or disappear depending on conditions. When camels are born, the humps are small and may appear deflated, but will grow as the calf begins to eat solid food. Adult camels that suffer extreme stress, such as heavy parasite loads, may lose their humps due to depletion of fat reserves. Captive plains bison may arch their backs (or "hump up") as a stress response, especially if in close confinement, which can create the illusion that their actual hump is much lower at the shoulders. Humps can take different forms, even between closely related species. The dromedary camel has only one hump, while the bactrian camel has two. This may be due to differences in fat metabolism rates, as the two-humped bactrian evolved lipid metabolism more rapidly. Yaks have humps comparable to the breastbone of a bird, while zebus have lump-like humps; when the two are crossbred, the yak's hump gene is dominant over the zebu's. In some cattle breeds, like the Drakensberger and Nguni, the hump is sexually dimorphic, with only bulls having one. In other breeds, like the Boran, both sexes have a hump, but it is larger in the male.
PCSK9 is a member of the peptidase S8 family. The solved structure of PCSK9 reveals four major components in the pre-processed protein: the signal peptide (residues 1-30); the N-terminal prodomain (residues 31–152); the catalytic domain (residues 153–425); and the C-terminal domain (residues 426–692), which is further divided into three modules. The N-terminal prodomain has a flexible crystal structure and is responsible for regulating PCSK9 function by interacting with and blocking the catalytic domain, which otherwise binds the epidermal growth factor-like repeat A (EGF-A) domain of the LDLR. While previous studies indicated that the C-terminal domain was uninvolved in binding LDLR, a recent study by Du et al. demonstrated that the C-terminal domain does bind LDLR. The secretion of PCSK9 is largely dependent on the autocleavage of the signal peptide and N-terminal prodomain, though the N-terminal prodomain retains its association with the catalytic domain. In particular, residues 61–70 in the N-terminal prodomain are crucial for its autoprocessing.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.